Mr. Nall is a healthcare executive with over 25 years of experience. He has been our President and CEO since 2013. Prior to joining Biocept, Michael served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement.
Michael joined Clarient in 2002 when it was a small publicly traded company and served in several leadership roles including Director, VP of Sales, VP of Sales and Reimbursement and finally GM. During the time Michael was with Clarient, the company grew to over $110 million in revenue and was acquired by GE Healthcare. Prior to joining Clarient, Michael was with Impath, an innovative cancer diagnostic company.
Michael moved to Diagnostics after an 11 year career in the medical device and equipment industry, representing products from manufacturers like Luxtec, Pall Biomedical, Horizon Medical, Davis and Geck and others.
Michael is a native of Kansas City, MO and has a BS in Business Administration from University of Central Missouri.
|Date||Type||Shares Traded||Price Range|
|Oct 19, 2016||Buy||36,363||1.10|
|Mar 9, 2016||Disposition (Non Open Market)||4,450||n/a|
|Mar 9, 2016||Acquisition (Non Open Market)||4,450||n/a|
|Feb 29, 2016||Acquisition (Non Open Market)||13,348||n/a|
|Sep 1, 2015||Disposition (Non Open Market)||4,762||n/a|
|Sep 1, 2015||Acquisition (Non Open Market)||4,762||n/a|
|Aug 24, 2015||Option Execute||14,286||n/a|
|Apr 30, 2015||Disposition (Non Open Market)||4,000||n/a|
|Apr 30, 2015||Acquisition (Non Open Market)||4,000||n/a|
|Feb 13, 2015||Buy||12,000||1.25|
Mark Foletta has over 30 years of audit and financial experience, with over 15 years in the biotechnology and pharmaceutical sectors. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. He is currently a member of the Board of Directors and Audit Committee of AMN Healthcare Services, Inc., a publicly traded healthcare workforce solutions provider, Dexcom, Inc. a publicly traded company and Regulus Therapeutics, Inc., a publicly traded biopharmaceutical company. He is also on the Board of Directors of Viacyte, Inc., a private biotechnology company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.
Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. Dr. Arnold recently founded Aegea Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, a rapidly emerging biotechnology company in Austin, Texas as well as on the board of Aegea. Previously he was VP, Research at Gen-Probe from September 2003 to October 2009.
He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder), where he was President and Chief Scientific Officer from October 2001 to September 2003. In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies; core to Gen-Probe assays that have generated more than $5B in product revenue. In addition, he has authored more than 50 scientific publications.
He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Dr. Singh brings to Biocept years of experience in laboratory diagnostics and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, Dr. Singh led the clinical laboratory team as the Medical Director at bioTheranostics where she oversaw growth in the CLIA laboratory test menu to incorporate offerings in solid tumor molecular analysis utilizing multiple methodologies and platforms including Next Generation Sequencing, RT-PCR and FISH. In addition, she has a wealth of experience in regulatory compliance (FDA, IVDMIA and Companion Diagnostics) and reimbursement. Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology.
Mr. Trivedi has more than 15 years of leadership experience in the biotechnology and diagnostic industry. He joins Biocept from Life Technologies. Before Life Technologies, Mr. Trivedi worked at Clarient, a GE Healthcare Company, where he lead marketing and business development. Prior to Clarient, Mr. Trivedi led commercial efforts and strategy for leukemia and lymphoma diagnostic services at US Labs, now part of LabCorp. He began his career at Ernst & Young LLP. Mr. Trivedi received a master's degree in Biotechnology from the University of Maryland and earned his bachelor's degree from the University of California, Irvine.
|Date||Type||Shares Traded||Price Range|
|Mar 24, 2014||Statement of Ownership||0||n/a|
Stock transaction information provided by EDGAR Online. Biocept Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.